FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crooke, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crooke, S. T.

The FASEB Journal, Vol 7, 533-539, Copyright © 1993 by The Federation of American Societies for Experimental Biology

REVIEWS

Progress toward oligonucleotide therapeutics: pharmacodynamic properties

ST Crooke
Isis Pharmaceuticals, Carlsbad, California 92008.

Although many issues remain to be resolved, recent progress suggests that oligonucleotides may have therapeutic potential. The first therapeutic oligonucleotide, ISIS 2105, an oligonucleotide designed to treat genital warts, has completed Phase I clinical trials and is undergoing Phase II testing. Conceptually, oligonucleotides may interact with nucleic acid or nonnucleic acid receptors; however, rational design of oligonucleotide drugs to interact with nucleic acid receptors is significantly simpler because the factors that determine affinity and selectivity are better understood. Recent progress demonstrates that this information can be coupled to rapid advances in the medicinal chemistry of oligonucleotides to create new generations of oligonucleotide drugs with dramatically improved properties. The purposes of this review are to place oligonucleotide therapeutics in the context of modern molecular drug discovery and to summarize progress in understanding the pharmacodynamic properties of oligonucleotides designed to bind to nucleic acid receptors. The pharmacokinetic and toxicologic properties of oligonucleotides have been reviewed recently (1-4). The activities of oligonucleotides that bind to nonnucleic acid receptors will be considered in future reviews.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. Matsushita, M. Hasegawa, T. Matsushita, M. Fujimoto, M. Horikawa, T. Fujita, A. Kawasuji, F. Ogawa, D. A. Steeber, T. F. Tedder, et al.
Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice
J. Immunol., July 1, 2007; 179(1): 698 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mani, C. M. Rudin, K. Kunkel, J. T. Holmlund, R. S. Geary, H. L. Kindler, F. A. Dorr, and M. J. Ratain
Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-{alpha} Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer
Clin. Cancer Res., April 1, 2002; 8(4): 1042 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Shi, R. J. Boado, and W. M. Pardridge
Antisense imaging of gene expression in the brain in vivo
PNAS, November 29, 2000; (2000) 250332397.
[Abstract] [Full Text]

Home page
 Vasc MedHome page
A. Ehsan and M. J Mann
Antisense and gene therapy to prevent restenosis
Vascular Medicine, May 1, 2000; 5(2): 103 - 114.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
C. M. Coulis, C. Lee, V. Nardone, and R. D. Prokipcak
Inhibition of c-myc Expression in Cells by Targeting an RNA-Protein Interaction Using Antisense Oligonucleotides
Mol. Pharmacol., March 1, 2000; 57(3): 485 - 494.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
D. K. Monteith and A. A. Levin
Synthetic Oligonucleotides: The Development of Antisense Therapeutics
Toxicol Pathol, January 1, 1999; 27(1): 8 - 13.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. A. Kolesnikov, Y.-X. Pan, A.-M. Babey, S. Jain, R. Wilson, and G. W. Pasternak
Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: Evidence for opposing NO actions on morphine analgesia and tolerance
PNAS, July 22, 1997; 94(15): 8220 - 8225.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
V. J. Dzau and M. Horiuchi
In Vivo Gene Transfer and Gene Modulation in Hypertension Research
Hypertension, December 1, 1996; 28(6): 1132 - 1137.
[Abstract] [Full Text]

Home page
 HypertensionHome page
D. Wielbo, A. Simon, M. I. Phillips, and S. Toffolo
Inhibition of Hypertension by Peripheral Administration of Antisense Oligodeoxynucleotides
Hypertension, July 1, 1996; 28(1): 147 - 151.
[Abstract] [Full Text]

Home page
 HypertensionHome page
D. Wielbo, C. Sernia, R. Gyurko, and M. I. Phillips
Antisense Inhibition of Hypertension in the Spontaneously Hypertensive Rat
Hypertension, March 1, 1995; 25(3): 314 - 319.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Shi, R. J. Boado, and W. M. Pardridge
Antisense imaging of gene expression in the brain in vivo
PNAS, December 19, 2000; 97(26): 14709 - 14714.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.